William W. Ho

1.6k total citations · 1 hit paper
21 papers, 514 citations indexed

About

William W. Ho is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, William W. Ho has authored 21 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in William W. Ho's work include Cancer Immunotherapy and Biomarkers (14 papers), Immunotherapy and Immune Responses (6 papers) and Dermatology and Skin Diseases (3 papers). William W. Ho is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Immunotherapy and Immune Responses (6 papers) and Dermatology and Skin Diseases (3 papers). William W. Ho collaborates with scholars based in United States, Singapore and Canada. William W. Ho's co-authors include Camille Blériot, Mathilde Bied, Florent Ginhoux, Rakesh K. Jain, Kosuke Kawaguchi, Dai Fukumura, Ashwin S. Kumar, Zohreh Amoozgar, Kangsan Roh and Hannah Curtis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

William W. Ho

18 papers receiving 509 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Roles of macrophages in tumor development: a spatiotemporal perspective

2023 178 citations Mathilde Bied, William W. Ho et al. Cellular and Molecular Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William W. Ho United States	8	266	235	162	64	44	21	514
Simon Tazzyman United Kingdom	4	301 1.1×	292 1.2×	149 0.9×	121 1.9×	27 0.6×	6	538
Felipe Gálvez‐Cancino Chile	11	362 1.4×	286 1.2×	136 0.8×	55 0.9×	36 0.8×	19	570
Nour Ershaid Israel	7	190 0.7×	228 1.0×	230 1.4×	63 1.0×	35 0.8×	8	464
Vera Petrova Germany	8	234 0.9×	173 0.7×	148 0.9×	62 1.0×	29 0.7×	15	420
Marie Laviron France	8	517 1.9×	260 1.1×	231 1.4×	67 1.0×	48 1.1×	8	688
Abhilash Gadi United States	13	97 0.4×	150 0.6×	376 2.3×	140 2.2×	39 0.9×	17	574
Swathi Yada Singapore	8	107 0.4×	232 1.0×	270 1.7×	54 0.8×	37 0.8×	11	586
Maria M. Steele United States	12	168 0.6×	319 1.4×	194 1.2×	66 1.0×	34 0.8×	20	494
Randall E. Ryan United States	8	238 0.9×	279 1.2×	160 1.0×	100 1.6×	17 0.4×	8	525
Valentina Robila United States	10	141 0.5×	129 0.5×	153 0.9×	64 1.0×	21 0.5×	25	359

Countries citing papers authored by William W. Ho

Since Specialization

Citations

This map shows the geographic impact of William W. Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William W. Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William W. Ho more than expected).

Fields of papers citing papers by William W. Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William W. Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William W. Ho. The network helps show where William W. Ho may publish in the future.

Co-authorship network of co-authors of William W. Ho

This figure shows the co-authorship network connecting the top 25 collaborators of William W. Ho. A scholar is included among the top collaborators of William W. Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William W. Ho. William W. Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dress, Regine J., William W. Ho, Jian Hang Lam, et al.. (2025). A Novel Polymersome Nanocarrier Promotes Anti‐Tumour Immunity by Improved Priming of CD8⁺ T Cells. Immunology. 175(1). 21–35.

Mahat, Dig Bijay, Heena Kumra, Kim B. Nguyen, et al.. (2025). Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer. Immunity. 58(7). 1688–1705.e9. 4 indexed citations

Ren, Jun, Zohreh Amoozgar, Pin‐Ji Lei, et al.. (2025). Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma. Proceedings of the National Academy of Sciences. 122(4). e2319474122–e2319474122. 2 indexed citations

Ho, William W. & Kong‐Peng Lam. (2025). Possible Roles for Purinergic Receptor P2RX4 in Breast and Prostate Cancers. International Journal of Molecular Sciences. 26(18). 9043–9043.

Talele, Nilesh P., Heena Kumra, Igor L. Gomes‐Santos, et al.. (2025). IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity. Journal for ImmunoTherapy of Cancer. 13(5). e011404–e011404. 1 indexed citations

Bied, Mathilde, William W. Ho, Florent Ginhoux, & Camille Blériot. (2023). Roles of macrophages in tumor development: a spatiotemporal perspective. Cellular and Molecular Immunology. 20(9). 983–992. 178 indexed citations breakdown →

Kim, Tae Min, Nuttapong Ngamphaiboon, Ki Hyeong Lee, et al.. (2023). 629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor. SHILAP Revista de lepidopterología. A1808–A1808. 1 indexed citations

Bissonnette, Robert, Janet DuBois, Paola Facheris, et al.. (2023). Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study. Allergy. 79(4). 924–936. 17 indexed citations

Lei, Pin‐Ji, Ethel R. Pereira, Zohreh Amoozgar, et al.. (2023). Cancer cell plasticity and MHC-II–mediated immune tolerance promote breast cancer metastasis to lymph nodes. The Journal of Experimental Medicine. 220(9). 35 indexed citations

10.

Adamik, Juraj, Rakesh K. Goyal, William W. Ho, et al.. (2023). 704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer. SHILAP Revista de lepidopterología. A799–A799. 1 indexed citations

11.

Brockstedt, Dirk G., Juraj Adamik, Rakesh K. Goyal, et al.. (2023). Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer.. Journal of Clinical Oncology. 41(16_suppl). 2625–2625.

12.

Guttman‐Yassky, Emma, Ana B. Pavel, Paola Facheris, et al.. (2022). 822 RPT193, a CCR4 inhibitor, improves the inflammatory skin transcriptomic profile in patients with atopic dermatitis. Journal of Investigative Dermatology. 142(8). S143–S143. 1 indexed citations

13.

Gomes‐Santos, Igor L., Zohreh Amoozgar, Ashwin S. Kumar, et al.. (2021). Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade. Cancer Immunology Research. 9(7). 765–778. 91 indexed citations

14.

Goyal, Rakesh K., et al.. (2021). 548 Phase 2 study of FLX475 in combination with ipilimumab in advanced melanoma. SHILAP Revista de lepidopterología. A578–A578. 1 indexed citations

15.

Nia, Hadi T., Meenal Datta, Giorgio Seano, et al.. (2020). In vivo compression and imaging in mouse brain to measure the effects of solid stress. Nature Protocols. 15(8). 2321–2340. 28 indexed citations

16.

Jorapur, Aparna, Oezcan Talay, David J. Wustrow, et al.. (2020). 561 Development and first-in-human characterization of a potent oral CCR4 antagonist for the treatment of atopic dermatitis. Journal of Investigative Dermatology. 140(7). S77–S77. 1 indexed citations

17.

Powderly, John D., Bartosz Chmielowski, Julie R. Brahmer, et al.. (2020). Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.. Journal of Clinical Oncology. 38(15_suppl). TPS3163–TPS3163. 4 indexed citations

18.

Jung, Keehoon, Takahiro Heishi, João Incio, et al.. (2017). Targeting CXCR4-dependent immunosuppressive Ly6C ^low monocytes improves antiangiogenic therapy in colorectal cancer. Proceedings of the National Academy of Sciences. 114(39). 10455–10460. 109 indexed citations

19.

O’Donnell, Peter H., M.S. Gordon, Kent C. Shih, et al.. (2012). 621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors. European Journal of Cancer. 48. 191–192. 27 indexed citations

20.

Chan, Rebecca L., et al.. (1988). Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys.. Pharmaceutical Research. 5(6). 335–340. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact